Satsuma Pharmaceuticals has presented phase 1 data on its second-generation nasal delivery device. The readout positions Satsuma to start a phase 3 clinical trial designed to enable it to bounce back ...
SUNNYVALE, Calif.--(BUSINESS WIRE)-- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced ...
Tenax Therapeutics (TENX) is in a very good position as far as its drug development plan goes for its drug levosimendan. That's because it is already in the process of running the ongoing phase 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results